.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Gastroenterology

UK Health Professionals Are Well Informed About Biosimilars

July 6th 2017

By Jackie Syrop

Article

A survey and drug utilization analysis conducted among UK healthcare professionals found that 75% of respondents were aware that biosimilars were available on their local formularies, and 77% considered biosimilars to be either extremely or very important to save costs for the National Health Service.

New Data Show Safe Switching From Reference Infliximab to CT-P13 in IBD

July 5th 2017

By Kelly Davio

Article

To date, only limited data have been available concerning long-term clinical outcomes of switching patients with inflammatory bowel disease (IBD) from reference infliximab (Remicade) to a biosimilar treatment. A new study concludes that a switch to CT-P13 from reference infliximab was both safe and feasible.

Patients' Reluctance to Accept Biosimilars Suggests Need for Better Communication, Education

April 20th 2017

By Jackie Syrop

Article